Items Tagged ‘lenvatinib’

January 25, 2018

Breakthrough Therapy Designation Awarded by FDA for Lenvima and Keytruda Combination Treatment for Advanced Renal Cell Carcinoma

By

CancerConnect News: The U.S. Food and Drug Administration (FDA) has announced “Breakthrough Therapy Designation” for the multiple receptor tyrosine kinase inhibitor Lenvima® (lenvatinib) in combination with Keytruda® (pembrolizumab) for the potential treatment of patients with advanced renal cell carcinoma (RCC). About Renal Cell Carcinoma Each year in the United States, more than 61,000 people are […]

View full entry

Tags: immunotherapy, keytruda, lenvatinib, Lenvima, News, pembrolizumab, Precision Cancer Medicine, Renal Cancer, renal cell cancer


May 28, 2015

Lenvima®

By

Class: Biological Therapy Generic Name: Lenvatinib Trade Name: Lenvima® For which conditions is this drug approved? Lenvima is approved to treat people with a type of thyroid cancer called differentiated thyroid cancer (DTC) when the disease can no longer be treated with radioactive iodine and is progressing. It is also indicated for patients with advanced renal […]

View full entry

Tags: Biological Therapy, differentiated thyroid cancer, Drug Dictionary, L, lenvatinib, Lenvima, Thyroid Cancer


May 28, 2015

Lenvatinib

By

Class: Biological Therapy Generic Name: Lenvatinib Trade Name: Lenvima® For which conditions is this drug approved? Lenvima is approved to treat people with a type of thyroid cancer called differentiated thyroid cancer (DTC) when the disease can no longer be treated with radioactive iodine and is progressing. It is also indicated for patients with advanced renal […]

View full entry

Tags: Biological Therapy, differentiated thyroid cancer, Drug Dictionary, L, lenvatinib, Lenvima, Thyroid Cancer


March 3, 2015

Lenvatinib; First Promising Treatment for Refractory Thyroid Cancer Patients in Years

By

In a pivotal Phase III study published in the New England Journal of Medicine, the oral anti-angiogenic therapy lenvatinib appears to be a very promising new treatment for patients with advanced radioiodine-refractory thyroid cancer. According to the National Cancer Institute, 60,000 people will be diagnosed with thyroid cancer in 2015 and almost 2,000 will die […]

View full entry

Tags: advanced radioiodine-refractory thyroid cancer, lenvatinib, New England Journal of Medicine, phase III, thyroid gland, tyrosine kinase inhibitors